<div id="readability-page-1"><div>Caudill Cortney Chief Operating Officer of Halozyme Therapeutics Inc [HALO] filed a Form 4 on December 19, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:<div><table><tbody><tr><th>Date</th><th>Transaction</th><th>Shares</th><th>Price</th><th>Value</th></tr><tr><td>11/1/25</td><td>Exercise</td><td>9,326</td><td>$0.00</td><td>N/A</td></tr><tr><td>11/1/25</td><td>Surrender(1)</td><td>4,263</td><td>$65.19</td><td>$277,905</td></tr></tbody></table></div>Ending Holdings: 12,737 - Direct<ul><li>(1)</li><li>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</li></ul>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data. </div></div>

HALO

Caudill Cortney, COO of Halozyme Therapeutics Inc, filed a Form 4 on December 19, 2025, disclosing the acquisition of 5,063 shares. The transactions included the exercise of 9,326 shares and the surrender of 4,263 shares to cover costs and taxes. Ending holdings are 12,737 shares directly.

COO Caudill Acquires 5,063 Of Halozyme Therapeutics Inc [HALO]